Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334601 | 0.98 | EPHX1 (0.67) | EPHX1MAPTALDH1A1GAATSHR | |
| SCHEMBL7198149 | 0.84 | EPHX1 (0.81) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL8393719 | 0.83 | EPHX1 (0.84) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL1424064 | 0.83 | EPHX1 (0.84) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL13590482 | 0.83 | EPHX1 (0.74) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL12126858 | 0.83 | NAMPT (0.53) | EPHX1MAPTALDH1A1GAATSHR | |
| Bicarbonate SCHEMBL6203780 | 0.82 | EPHX1 (0.82) | EPHX1ALDH1A1GAATSHRMEN1 | |
| Cyclobutylcarbamic Acid Benzyl Ester SCHEMBL332814 | 0.81 | EPHX1 (0.76) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL7000390 | 0.81 | EPHX1 (0.71) | EPHX1ALDH1A1GAATSHRMEN1 | |
| Methyl Alcohol SCHEMBL6780968 | 0.81 | EPHX1 (0.80) | EPHX1ALDH1A1GAATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | claimed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | GPR119, GLP1R, ADIPOR1 | EPHX1 2550/4885MAPT 4163/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.